Business Description
Cytek Biosciences Inc
NAICS : 423450
SIC : 3845
ISIN : US23285D1090
Total Employee Number:
702Description
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 9.54 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -1.17 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 3.46 | |||||
Beneish M-Score | -3.5 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10 | |||||
3-Year FCF Growth Rate | 24.3 | |||||
3-Year Book Growth Rate | -5.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.81 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 76.3 | |||||
9-Day RSI | 66.49 | |||||
14-Day RSI | 60.41 | |||||
3-1 Month Momentum % | -13.32 | |||||
6-1 Month Momentum % | -22.16 | |||||
12-1 Month Momentum % | 11.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.69 | |||||
Quick Ratio | 4.07 | |||||
Cash Ratio | 3.24 | |||||
Days Inventory | 181.14 | |||||
Days Sales Outstanding | 100.94 | |||||
Days Payable | 25.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.7 | |||||
Shareholder Yield % | -0.9 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 51.7 | |||||
Operating Margin % | -21.49 | |||||
Net Margin % | -36.25 | |||||
EBITDA Margin % | -11.56 | |||||
FCF Margin % | -6.29 | |||||
OCF Margin % | -3.57 | |||||
ROE % | -20.5 | |||||
ROA % | -15.54 | |||||
ROIC % | -22.71 | |||||
3-Year ROIIC % | -266.9 | |||||
ROC (Joel Greenblatt) % | -42.56 | |||||
ROCE % | -8.85 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 360.65 | |||||
PS Ratio | 2.79 | |||||
PB Ratio | 1.76 | |||||
Price-to-Tangible-Book | 1.95 | |||||
EV-to-EBIT | -9.61 | |||||
EV-to-EBITDA | -14.46 | |||||
EV-to-Revenue | 1.67 | |||||
EV-to-Forward-Revenue | 12.66 | |||||
EV-to-FCF | -26.58 | |||||
Price-to-GF-Value | 0.77 | |||||
Price-to-Projected-FCF | 2.19 | |||||
| Price-to-Net-Current-Asset-Value | 2.23 | |||||
| Price-to-Net-Cash | 4.09 | |||||
Earnings Yield (Greenblatt) % | -10.41 | |||||
FCF Yield % | -2.23 |
Cytek Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cytek Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 132 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 131 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | In 41 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 40 days | ||
| Singular Research’s Las Vegas Invitational Conference | 2026-06-15 11:00 | 3.96 (-2.46%) | ||
| General meeting for 2026 | 2026-06-10 11:00 | 4.13 (+1.72%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 4.94 (+2.70%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 4.94 (+2.70%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-04 11:10 | 4.44 (+3.98%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 16:30 | 4.37 (-0.91%) |
Show
Entries
Guru Commentaries on NAS:CTKB
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Cytek Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers